Statins and serum cholesterol's associations with incident dementia and mild cognitive impairment

Journal of Epidemiology and Community Health

Volumn 65, Issue 11, 2011, Pages 949-957

  Beydoun, May A ^a   Beason Held, Lori L ^a   Kitner Triolo, Melissa H ^a   Beydoun, Hind A ^b   Ferrucci, Luigi ^a   Resnick, Susan M ^a   Zonderman, Alan B ^a  

^a NATIONAL INSTITUTE ON AGING   (United States)

^b EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

FAT; HEALTH RISK; LIPID; PROTEIN; RISK FACTOR; SERUM;

ADULT; AGED; ARTICLE; BLOOD; DEMENTIA; DRUG EFFECT; FEMALE; HUMAN; LONGITUDINAL STUDY; MALE; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; UNITED STATES;

ADULT; AGED; AGED, 80 AND OVER; BALTIMORE; CHOLESTEROL, LDL; DEMENTIA; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; YOUNG ADULT;

EID: 80955135450     PISSN: 0143005X     EISSN: 14702738     Source Type: Journal    
DOI: 10.1136/jech.2009.100826     Document Type: Article

References (46)

1. Hajjar I, Schumpert J, Hirth V, et al. The impact of the use of statins on the prevalence of dementia and the progression of cognitive impairment. J Gerontol A Biol Sci Med Sci 2002;57:M414-18.
2. Bernick C, Katz R, Smith NL, et al. Statins and cognitive function in the elderly: the Cardiovascular Health Study. Neurology 2005;65:1388-94.
3. Szwast SJ, Hendrie HC, Lane KA, et al. Association of statin use with cognitive decline in elderly African Americans. Neurology 2007;69:1873-80.
4. Dufouil C, Richard F, Fievet N, et al. APOE genotype, cholesterol level, lipid-lowering treatment, and dementia: the Three-City Study. Neurology 2005;64:1531-8.
5. Jick H, Zornberg GL, Jick SS, et al. Statins and the risk of dementia. Lancet 2000;356:1627-31.
6. Rockwood K, Darvesh S. The risk of dementia in relation to statins and other lipid lowering agents. Neurol Res 2003;25:601-4.
7. Zamrini E, McGwin G, Roseman JM. Association between statin use and Alzheimer's disease. Neuroepidemiology 2004;23:94-8.
8. Zhou B, Teramukai S, Fukushima M. Prevention and treatment of dementia or Alzheimer's disease by statins: a meta-analysis. Dement Geriatr Cogn Disord 2007;23:194-201.
9. Haag MD, Hofman A, Koudstaal PJ, et al. Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam Study. J Neurol Neurosurg Psychiatry 2009;80:13-17.
10. Sparks DL, Kryscio RJ, Sabbagh MN, et al. Reduced risk of incident AD with elective statin use in a clinical trial cohort. Curr Alzheimer Res 2008;5:416-21.
11. Cramer C, Haan MN, Galea S, et al. Use of statins and incidence of dementia and cognitive impairment without dementia in a cohort study. Neurology 2008;71:344-50.
12. Arvanitakis Z, Schneider JA, Wilson RS, et al. Statins, incident Alzheimer disease, change in cognitive function, and neuropathology. Neurology 2008;70:1795-802.
13. Desmond DW, Tatemichi TK, Paik M, et al. Risk factors for cerebrovascular disease as correlates of cognitive function in a stroke-free cohort. Arch Neurol 1993;50:162-6.
14. Elias PK, Elias MF, D'Agostino RB, et al. Serum cholesterol and cognitive performance in the Framingham Heart Study. Psychosom Med 2005;67:24-30.
15. Kivipelto M, Helkala EL, Laakso MP, et al. Apolipoprotein E epsilon4 allele, elevated midlife total cholesterol level, and high midlife systolic blood pressure are independent risk factors for late-life Alzheimer disease. Ann Intern Med 2002;137:149-55.
16. Solomon A, Kareholt I, Ngandu T, et al. Serum cholesterol changes after midlife and late-life cognition: twenty-one-year follow-up study. Neurology 2007;68:751-6.
17. Stewart R, Richards M, Brayne C, et al. Vascular risk and cognitive impairment in an older, British, African-Caribbean population. J Am Geriatr Soc 2001;49:263-9.
18. Wada T, Matsubayashi K, Okumiya K, et al. Lower serum cholesterol level and later decline in cognitive function in older people living in the community, Japan. J Am Geriatr Soc 1997;45:1411-12.
19. Crisby M. The role of pleiotropic effects of statins in dementia. Acta Neurol Scand Suppl 2006;185:115-18.
20. Shock N, Greulich RC, Andres R, et al. Normal human aging: the Baltimore Longitudinal Study of Aging. Washington, DC: US Government Printing Office, 1984.
21. Blessed G, Tomlinson BE, Roth M. The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects. Br J Psychiatry 1968;114:797-811.
22. Morris JC. Clinical dementia rating: a reliable and valid diagnostic and staging measure for dementia of the Alzheimer type. Int Psychogeriatr 1997;9(Suppl 1):173-6; discussion 7-8.
23. Kawas C, Segal J, Stewart WF, et al. A validation study of the dementia questionnaire. Arch Neurol 1994;51:901-6.
24. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd edn. Revised. Washington, DC: American Psychiatric Association, 1987.
25. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-44.
26. Morris JC. The clinical dementia rating (CDR): current version and scoring rules. Neurology 1993;43:2412-14.
27. Vitaliano PP, Breen AR, Russo J, et al. The clinical utility of the dementia rating scale for assessing Alzheimer patients. J Chronic Dis 1984;37:743-53.
28. Kawas C, Gray S, Brookmeyer R, et al. Age-specific incidence rates of Alzheimer's disease: the Baltimore longitudinal study of aging. Neurology 2000;54:2072-7.
29. Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med 2004;256:183-94.
30. 2+ precipitation procedure for quantitation of high-density-lipoprotein cholesterol. Clin Chem 1982;28:1379-88.
31. STATA. Statistics/data analysis: release 10.0. College Station, TX: Stata Corporation, 2007.
32. Rockwood K. Epidemiological and clinical trials evidence about a preventive role for statins in Alzheimer's disease. Acta Neurol Scand Suppl 2006;185:71-7.
33. Sturmer T, Joshi M, Glynn RJ, et al. A review of the application of propensity score methods yielded increasing use, advantages in specific settings, but not substantially different estimates compared with conventional multivariable methods. J Clin Epidemiol 2006;59:437-47.
34. Wolozin B, Kellman W, Ruosseau P, et al. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol 2000;57:1439-43.
35. Xiong GL, Benson A, Doraiswamy PM. Statins and cognition: what can we learn from existing randomized trials? CNS Spectr 2005;10:867-74.
36. Muldoon MF, Flory JD, Ryan C. Serum cholesterol, the brain, and cognitive functioning. Mahwah, NJ: Lawrence Erlbaum Associates, 2001.
37. Alexopoulos CG, Pournaras S, Vaslamatzis M, et al. Changes in serum lipids and lipoproteins in cancer patients during chemotherapy. Cancer Chemother Pharmacol 1992;30:412-16.
38. Kaplan JR, Manuck SB, Fontenot MB, et al. The cholesterol-serotonin hypothesis: interrelationships among dietary lipids, central serotonergic activity, and social behavior in monkeys. Washington, DC: American Psychology Association, 1997.
39. Yaffe K, Barrett-Connor E, Lin F, et al. Serum lipoprotein levels, statin use, and cognitive function in older women. Arch Neurol 2002;59:378-84.
40. Refolo LM, Malester B, LaFrancois J, et al. Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. Neurobiol Dis 2000;7:321-31.
41. Rajanikant GK, Zemke D, Kassab M, et al. The therapeutic potential of statins in neurological disorders. Curr Med Chem 2007;14:103-12.
42. Birkenhager WH, Wang JG, Staessen JA. Dementia and statins. Lancet 2001;357:880; author reply -1.
43. Morell CH, Brant LJ, Pearson JD, et al. Applying linear mixed-effects models to the problem of measurement error in epidemiologic studies. Commun Stat 2003;32:437-59.
44. Breitner JC, Haneuse SJ, Walker R, et al. Risk of dementia and AD with prior exposure to NSAIDs in an elderly community-based cohort. Neurology 2009;72:1899-905.
45. in t' Veld BA, Ruitenberg A, Hofman A, et al. Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N Engl J Med 2001;345:1515-21.
46. Singer JD, Willet JB, eds. Applied longitudinal data analysis: modeling change and event occurrence. New York: Oxford University Press, 2003.